28547-12-8

Upstream product

• 94-09-7 p-aminoethylbenzoate 
• 150-13-0 4-amino-benzoic acid 
• 100-07-2 4-methoxy-benzoyl chloride 
• 100278-51-1 Ethyl-4-(4-methoxybenzoylamino)benzoate 
• 100-09-4 4-methoxybenzoic acid 

Downstream Products

• 1258550-57-0 4-methoxy-N-(4-(3-nitro-4-(2-(phenylthio)ethylamino)phenylsulfonylcarbamoyl)phenyl)benzamide 
• 1369423-89-1 C₂₄H₂₀N₄O₅S₂ 
• 1130590-39-4 4-(4-methoxybenzamido)benzoyl chloride 
• 1369423-94-8 C₂₅H₂₂N₄O₅S₂ 
• 1360606-73-0 C₂₂H₂₁N₅O₄ 
• 1360606-67-2 C₂₁H₁₉N₅O₄ 
• 68962-74-3 4-methoxy-N-[4-(morpholine-4-carbonyl)-phenyl]-benzamide 

Relevant academic research and scientific papers

Thermoplastic polymer composition

The invention provides a compound conforming to the structure of Formula (C) The invention also provides a thermoplastic polymer composition comprising a polyolefin polymer and a compound conforming to the structure of Formula (C) as a nucleating agent.

Design, synthesis and insulin-sensitising effects of novel PTP1B inhibitors

Fifteen novel sulfathiazole-related compounds were designed as PTP1B inhibitors based on a previously reported allosteric inhibitor (1) of PTP1B. These compounds were synthesized and evaluated against human recombinant PTP1B. Six compounds (3, 4, 8 and 14

Design and synthesis of 8-substituted benzamido-phenylxanthine derivatives as MAO-B inhibitors

Monoamine oxidase-B (MAO-B) inhibitor has been used as neuroprotectants to treat the motor deficits of Parkinson's disease (PD). We designed and synthesized a class of 8-substituted benzamido-phenylxanthine derivatives as MAO-B inhibitors. The compounds have various inhibitory effects, with compound 6a having a Ki value of 0.26 lM. Their promising activity in vitro suggests potential use in the treatment of PD.

Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: Characteristics of broad-spectrum protein binding and its effects on anti-tumor activity

On the basis of the comparison of the structure of the Bim BH3: Bcl-x L complex and that of the ABT-737: Bcl-xL complex, a series of class A compounds were designed. These compounds had the basic skeleton of ABT-737 and the h2 residues of Bim BH3. These residues had shown themselves to be relevant to Bim BH3's broad-spectrum binding properties in saturation mutagenesis assays. Unlike ABT-737, which is a selective inhibitor of anti-apoptotic members of the Bcl-2 protein family, the class A compounds showed broad-spectrum binding activity to target proteins similar to those of Bim BH3 peptide. Then class B compounds were synthesized by modifying the structure of the most effective class A compound, A-4. Most of these class B compounds showed better binding affinity to the target proteins than the class A compounds had. They also showed themselves more effective than ABT-737 at inhibiting growth in multiple tumor cell lines known to express Bcl-x L, Bcl-2, and Mcl-1 proteins at high levels. Compounds B-11 and B-12 had the strongest anti-tumor activity of any compounds we produced. This study suggests that it is feasible to design small-molecule inhibitors based on the structure of Bim BH3, which shows broad-spectrum binding to Bcl-xL, Bcl-2, and Mcl-1 proteins. Our results also suggest that the broad-spectrum properties of small-molecule inhibitors binding to target proteins play a critical role in inhibiting the growth of many tumor cells. Finally, our study provides a series of lead compounds that merit further research into anti-cancer therapeutics.

Synthesis of some alkoxybenzamide derivatives as smooth muscle relaxant agents.

The preparation of 16 new N-substituted p-aminobenzamide derivatives which contain diethylaminoethyl-N-methylpiperazine, piperidine and morpholine moieties were described. Preliminary pharmacological testing of representative compounds showed that some of the prepared compounds possess anticholinergic and antihistaminic activities.